Industry News
Biotechnology Industry News
A pivotal study of a Takeda…
A pivotal study of a Takeda primary immunodeficiency disease (PID) asset has hit its primary endpoint, demonstrating pharmacokinetic (PK) comparability between the asset and HyQvia, which was approved to treat PID in 2014.
Windward Bio is in full sail with…
Windward Bio is in full sail with a $165 million crossover financing to push its long-acting anti-TSLP antibody into phase 3, betting that a twice-yearly dosing schedule will be a key differentiator in an increasingly
Funding for privately traded Swiss…
Funding for privately traded Swiss biotechs hit a new high last year, climbing 38% to 1.15 billion Swiss francs ($1.5 billion). However, a relatively small pool of companies drove the funding jump while many of
UCB has struck a deal to acquire…
UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merger with Rallybio to challenge Gilead for an emerging opportunity for T-cell engagers.
A cross-section of biotech leaders…
A cross-section of biotech leaders is launching the American Biotech Innovation Alliance (ABIA) with the goal of uniting stakeholders and defining a national strategy to sustain and expand U.S. leadership in biotech innovation.
Katherine Szarama, Ph.D., will…
Katherine Szarama, Ph.D., will take over as CBER director in an acting capacity while the search for a permanent director continues.
Viking Therapeutics’…
Viking Therapeutics’ collaboration with Ligand Pharmaceuticals has sailed into some trouble, with one of the partners keen to jettison part of the pact.
Johnson & Johnson has dropped…
Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliver peak sales north of $5 billion.
“We want to develop those programs…
"We want to develop those programs as far as we can ourselves,” Seaport CEO Daphne Zohar told Fierce.
Amgen has pulled the plug on…
Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating five clinical trials in the process.
As MRD shifts from prognostic…
As MRD shifts from prognostic marker to intervention trigger, sponsors must rethink trial design, endpoints and decision-making.
After last month’s departure of…
After last month’s departure of longtime executive Adam Pearson, Astellas has picked out a new strategist to fill the open spot on its C-suite with Takahiko Iwaya, who takes over as chief strategy officer on
Curium’s Mike Patterson on…
Curium’s Mike Patterson on improving access, safety and trust to scale theranostics and enhance patient care.
An FDA expert panel on Thursday…
An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca's proposal of using its oral SERD camizestrant in a novel first-line switch setting in HR-positive, HER2-negative metastatic breast cancer, dealing an early blow
The Trump administration’s support…
The Trump administration's support could launch psychedelics across the regulatory finish line or doom the field to perpetual questions of legitimacy.
Bristol Myers Squibb has called…
Bristol Myers Squibb has called time on a bispecific antibody partnership with Zymeworks that the Big Pharma inherited from Celgene.
Indivior ended internal…
Indivior ended internal development of an opioid use disorder candidate after a phase 2 trial missed its primary endpoint.
BeOne Medicines is paying $20…
BeOne Medicines is paying $20 million upfront to reserve the right to buy a preclinical PD-1xCTLA-4xVEGF trispecific antibody from China’s Huahui Health.
Danish dermatology specialist Leo…
Danish dermatology specialist Leo Pharma is paying $50 million for U.S. gene writing biotech Replay and its preclinical gene therapy for a rare skin disease.
GSK and Alector have stopped a…
GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the study was unlikely to hit its primary endpoint.